Compare ENTG & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTG | EXAS |
|---|---|---|
| Founded | 1966 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 11.0B |
| IPO Year | 2000 | N/A |
| Metric | ENTG | EXAS |
|---|---|---|
| Price | $89.12 | $101.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 20 |
| Target Price | ★ $98.25 | $76.38 |
| AVG Volume (30 Days) | 2.8M | ★ 10.3M |
| Earning Date | 10-30-2025 | 11-03-2025 |
| Dividend Yield | ★ 0.45% | N/A |
| EPS Growth | ★ 26.59 | N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $3,222,508,000.00 | $3,082,033,000.00 |
| Revenue This Year | $0.27 | $19.40 |
| Revenue Next Year | $6.22 | $13.51 |
| P/E Ratio | $46.93 | ★ N/A |
| Revenue Growth | 0.59 | ★ 14.47 |
| 52 Week Low | $60.75 | $38.81 |
| 52 Week High | $112.36 | $101.87 |
| Indicator | ENTG | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 61.29 | 89.74 |
| Support Level | $72.23 | $100.98 |
| Resistance Level | $75.13 | $101.43 |
| Average True Range (ATR) | 3.62 | 2.25 |
| MACD | 2.05 | 0.53 |
| Stochastic Oscillator | 95.30 | 97.74 |
Entegris is a leading supplier of purification solutions and advanced materials. The vast majority of sales are to the semiconductor industry. The majority of revenue comes from semiconductor fabricators, but the company sells to all areas of the semiconductor manufacturing supply chain including equipment and engineering, chemicals and materials, and distributors. Entegris specializes in materials science and materials purity, both of which are crucial in the semiconductor manufacturing process.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.